Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu